HIMS · Hims & Hers Health, Inc.

Current Thesis

Hims & Hers Health's recovery case is that revenue growth can withstand billing scrutiny; delivery of its third-quarter revenue guidance and recovery of the $29.53 conversion reference would substantiate that case. This is a new repair hypothesis: the previous thesis was invalidated when the market closed at $28.84 on Friday, 2026-08-28, below its published $29 boundary. The 2026-09-11 adjusted close of $27.51 shows that the lost level remains unrecovered.

As an interpretation of that record, the narrative is maturing — the growth reset announced on 2026-08-10 now awaits another operating test, while September options coverage has accompanied a price below the previous thesis boundary. The recovery hypothesis fails on a subsequent weekly close below $27.51, the latest public reference close; that number is an observation anchor, not an established support shelf.

Bullish and bearish views on Hims & Hers Health, Inc.

The model's bull view on Hims & Hers Health, Inc. (HIMS), in brief: Revenue exceeded the prior guide. The 2026-08-10 results reported second-quarter revenue of $753.2 million, up 38% year over year, above management's $680–700 million guidance. This establishes reported growth, without establishing its durability. Company results Management… The bear view: Growth came with margin deterioration. The 2026-08-10 release reported second-quarter gross margin of 64%, versus 76% a year earlier, and a net loss of $86.3 million. A subsequent gross margin below 64% would contradict margin stabilization. Company results Billing scrutiny… Both cases follow in full.

Bull Case

• Revenue exceeded the prior guide. The 2026-08-10 results reported second-quarter revenue of $753.2 million, up 38% year over year, above management's $680–700 million guidance. This establishes reported growth, without establishing its durability. Company results
• Management raised the revenue hurdle. On 2026-08-10, management guided third-quarter revenue to $880–900 million and full-year revenue to $3.1–3.3 billion. Third-quarter revenue below $880 million would reject the operating premise of the recovery case. Company results
• Subscription metrics support the mechanism. At 2026-06-30, subscribers numbered 2.891 million, up 19% year over year; second-quarter monthly revenue per average subscriber was $92, up 21%. These reported measures support broader participation and greater spending, but do not isolate retention after billing changes. Company results

Bear Case

• Growth came with margin deterioration. The 2026-08-10 release reported second-quarter gross margin of 64%, versus 76% a year earlier, and a net loss of $86.3 million. A subsequent gross margin below 64% would contradict margin stabilization. Company results
• Billing scrutiny remains operationally relevant. Bloomberg reported on 2026-08-21 that July weight-loss subscription disputes exceeded Visa's 1.5% threshold, triggering monitoring. The Federal Trade Commission, California and Utah separately filed their complaint on 2026-07-29; the allegations remain allegations, and the card-network report does not establish their legal merits.
• September coverage recirculated older measurements. Benzinga's 2026-09-01 headline cited 990 adverse-event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide. The Food and Drug Administration (FDA) dates those totals to 2026-05-31, does not identify them as Hims-specific, and cautions that causation cannot always be determined. They do not establish a September deterioration at Hims. FDA safety statement

Setup & Price Structure

The adjusted daily series records a $27.51 close on 2026-09-11, 56.2% below its $62.76 trailing-year high, with a three-month price increase of 2.6%. The 14-period relative strength index (RSI) was 28.1. Those measurements describe weak recent momentum; they do not establish a reversal. No moving-average value or trading-volume series is available to establish a rising support line or expanding participation.

The market remains below the former $29 thesis boundary and the $29.53 conversion reference associated with the May 2026 convertible financing. The latter supplies an observable recovery checkpoint, but a conversion price alone does not prove imminent issuance or selling pressure.

Benzinga options-activity coverage recurred on 2026-09-02 and 2026-09-07, following 2026-08-12 and 2026-08-21 alerts. That is evidence of coverage clustering. Without contract direction, open interest, comparable volume or short-interest measurements, this small sample supports no conclusion about bullish crowding or an impending squeeze.

Catalyst Calendar (next 30 days)

• ~2026-09-30, estimated billing checkpoint. Bloomberg's 2026-08-21 report placed a roughly $75,000 Visa dispute-surcharge bill in September; the precise payment date is unconfirmed. Payment would not itself demonstrate improved cancellation practices or clearance from monitoring.

No confirmed company event within the next 30 days was identified on the investor calendar checked on 2026-09-13. The estimated billing checkpoint therefore does not supply a confirmed catalyst date. Company event calendar

• ~2026-11-09, estimated earnings date. This remains an unconfirmed timing estimate for third-quarter results, outside the immediate window. The report is the substantive test of the revenue guidance issued on 2026-08-10 and whether gross margin stabilizes. Company event calendar

What Would Change Our Mind

Failure to retain the latest observed weekly closing level would end the repair hypothesis: a weekly close below $27.51 breaches the 2026-09-11 reference. This does not reverse the previous thesis's invalidation below $29 on 2026-08-28.

The affirmative test requires third-quarter revenue of at least $880 million, gross margin of at least 64%, and a weekly close above $29.53 by the first weekly close following the third-quarter report. These are explicit research conditions drawn from the 2026-08-10 guidance, second-quarter margin and May financing reference. Failure of either operating threshold rejects the recovery case even if the price boundary remains intact.

Correlation Notes

The 2026-09-01 and 2026-09-02 headlines connect Hims coverage to glucagon-like peptide-1 (GLP-1) weight-loss medicines. However, the FDA's statement says its ingredient import alert preserves lawful imports from compliant manufacturers and creates no new limits on legal compounding; it does not establish a Hims supply interruption. FDA safety statement

This remains a single-name recovery hypothesis. No paired return series is available as of 2026-09-13 to establish correlation with drug manufacturers, telehealth peers or a broader healthcare rally; the dated options headlines cannot substitute for that measurement.